| Title |
No man’s land: information needs and resources of men with metastatic castrate resistant prostate cancer
|
|---|---|
| Published in |
Supportive Care in Cancer, July 2016
|
| DOI | 10.1007/s00520-016-3358-0 |
| Pubmed ID | |
| Authors |
V. A. Jenkins, L. J. Fallowfield |
| Abstract |
The majority of men treated for prostate cancer will eventually develop castrate-resistant disease (CRPC) with metastases (mCRPC). There are several options for further treatment: chemotherapy, third-line hormone therapy, radium, immunotherapy, and palliation. Current ASCO guidelines for survivors of prostate cancer recommend that an individual's information needs at all stages of disease are assessed and that patients are provided with or referred to the appropriate sources for information and support. Earlier reviews have highlighted the dearth of such services and we wished to see if the situation had improved more recently. Unfortunately, we conclude that there is still a lack of good-quality congruent information easily accessible specifically for men with mCRPC and insufficient data regarding the risks, harms, and benefits of different management plans. More research providing a clear evidence base about treatment consequences using patient reported outcome measures is required. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ireland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 27 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 22% |
| Unspecified | 5 | 19% |
| Student > Doctoral Student | 3 | 11% |
| Student > Ph. D. Student | 3 | 11% |
| Other | 2 | 7% |
| Other | 4 | 15% |
| Unknown | 4 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Nursing and Health Professions | 7 | 26% |
| Unspecified | 5 | 19% |
| Medicine and Dentistry | 5 | 19% |
| Social Sciences | 3 | 11% |
| Psychology | 2 | 7% |
| Other | 1 | 4% |
| Unknown | 4 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2016.
All research outputs
#20,342,896
of 22,889,074 outputs
Outputs from Supportive Care in Cancer
#4,021
of 4,597 outputs
Outputs of similar age
#320,243
of 365,680 outputs
Outputs of similar age from Supportive Care in Cancer
#59
of 69 outputs
Altmetric has tracked 22,889,074 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,597 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,680 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.